StreetInsider.com News Articles

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 15

Wed, 15 Jul 2026 13:26:00 -0400

si-local-file:///var/storage/secattach/20260715/26773414.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 15

Wed, 15 Jul 2026 13:26:00 -0400

si-local-file:///var/storage/secattach/20260715/26773414.html

Eupraxia Pharmaceuticals (EPRX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 15 Jul 2026 07:47:06 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).

The analyst commented, "Why meet? Eupraxia has a major catalyst in December with the Phase 2b data for EP-104GI (extended-release formulation of fluticasone propionate) in eosinophilic esophagitis (EoE; inflammatory GI disorder). The conference will serve as a good opportunity to focus on the endpoints that carry the most weight, get a refresher on what the commercial landscape looks like today, and iron any last questions out ahead of the readout. Where we'll differentiate: We believe the Street hasn't fully grasped and understood the

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 13

Mon, 13 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260713/26762648.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 13

Mon, 13 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260713/26762648.html

Eupraxia Pharmaceuticals adds executives, shifts operations to Vancouver

Mon, 13 Jul 2026 16:06:05 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) announced changes to its executive leadership team and operating structure, according to a press release dated July 13, 2026.

Dr. Jeff Millard joined the company as Executive Vice President, Technical Operations, effective July 13, 2026. He brings nearly 25 years of experience in technical operations, chemistry, manufacturing and controls, and regulatory strategy, having previously held senior roles at Ensysce Biosciences, Microbion Corporation, and Cascadian Therapeutics.

Dr. Alex Therien, who joined Eupraxia in November 2025, will assume leadership of Research and Development as Executive Vice President. He has more than 20 years of biopharmaceutical experience, including senior roles

Eupraxia Pharmaceuticals adds executives, shifts operations to Vancouver

Mon, 13 Jul 2026 16:06:05 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) announced changes to its executive leadership team and operating structure, according to a press release dated July 13, 2026.

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

Mon, 13 Jul 2026 16:05:00 -0400

VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced updates to its executive leadership and operating structure as the Company continues to prepare for its next stage of clinical and commercial development.

Dr. Jeff Millard has joined Eupraxia as Executive Vice President, Technical Operations, effective July 13, 2026. Dr. Millard brings nearly 25 years of leadership experience in technical operations, CMC

Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth

Mon, 13 Jul 2026 16:05:00 -0400

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 07

Tue, 07 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260707/26742036.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 07

Tue, 07 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260707/26742036.html

Eupraxia Pharmaceuticals adds three directors to its board

Tue, 07 Jul 2026 08:02:55 -0400

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) has appointed Robert Bazemore, Amy Pott, and Dr. Helen Thackray to its board of directors, according to a press release from the Vancouver-based clinical-stage biotechnology company.

Bazemore has more than 30 years of experience in drug development and commercialization. He served as president, chief executive officer, and director of Epizyme Inc. from 2015 to 2021, where he oversaw the launch of TAZVERIK. He previously held the role of president of Janssen Biotech at Johnson & Johnson and spent over 11 years at Merck & Co. He currently serves as a director at Nuvation Bio, Ardelyx, and

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

Tue, 07 Jul 2026 08:00:00 -0400

VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors.

"We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development,

Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization

Tue, 07 Jul 2026 08:00:00 -0400

Oppenheimer Starts Eupraxia Pharmaceuticals (EPRX) at Outperform

Thu, 25 Jun 2026 16:32:44 -0400

(Updated - June 25, 2026 4:32 PM EDT)

Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Outperform rating and a price target of $17.00.

The analyst commented: "We initiate coverage of Eupraxia Pharmaceuticals with an Outperform rating and $17 PT, reflecting the differentiated potential for lead asset EP-104GI in eosinophilic esophagitis (EoE), an underappreciated indication dominated by burdensome steroids and high-cost biologics. By delivering sustained, localized fluticasone via a once-yearly endoscopic procedure, EP-104GI appears well-positioned to address a significant treatment gap where adherence remains critically challenging, supported by KOL feedback and prior Ph1b/2a data showing durable remission

Oppenheimer Starts Eupraxia Pharmaceuticals (EPRX) at Outperform

Thu, 25 Jun 2026 16:32:44 -0400

(Updated - June 25, 2026 4:32 PM EDT)

Oppenheimer analyst Jay Olson initiates coverage on Eupraxia Pharmaceuticals (NASDAQ: EPRX) with a Outperform rating and a price target of $17.00.

Eupraxia Pharmaceuticals (EPRX) Reiterated at Overweight by Cantor Fitzgerald

Thu, 25 Jun 2026 07:23:09 -0400

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $19.00 price target on Eupraxia Pharmaceuticals (NASDAQ: EPRX).

The analyst commented, "We hosted Eupraxia management for a well-attended three-day NDR in California and Colorado. EPRX is a Top Pick. Recall that Eupraxia's lead candidate, EP-104GI (extended-release formulation of fluticasone propionate, a steroid), is in Phase 2b development in eosinophilic esophagitis (EoE; inflammatory GI disorder). Data are expected in 4Q26."

For an analyst ratings summary and ratings history on Eupraxia Pharmaceuticals click here. For more ratings news on Eupraxia Pharmaceuticals click here.

Shares of Eupraxia Pharmaceuticals closed at $6.25 yesterday.

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 19

Mon, 22 Jun 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26671521.html

Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 19

Mon, 22 Jun 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260622/26671521.html

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders